MB097
Advanced Melanoma (co-therapy with immune checkpoint inhibitors)
Phase 1bActive
Key Facts
Indication
Advanced Melanoma (co-therapy with immune checkpoint inhibitors)
Phase
Phase 1b
Status
Active
Company
About Microbiotica
Microbiotica is a UK-based, clinical-stage biotech translating microbiome science into defined live biotherapeutic medicines. Founded in 2016 as a spin-out from the Wellcome Sanger Institute, the company has raised £62M to date and is advancing two lead clinical programs: MB097 for enhancing immunotherapy in melanoma and MB310 for ulcerative colitis. Its core strength is a precision microbiome profiling platform that identifies bacterial signatures from clinical data to develop targeted therapies for specific patient populations.
View full company profile